Cargando…
Refreshing the biologic pipeline 2020
In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7842168/ https://www.ncbi.nlm.nih.gov/pubmed/33510484 http://dx.doi.org/10.1038/s41587-021-00814-w |